2021 is the first year of the "14th five year plan" and the historical intersection of the "two centenary" goals. It is also a key period for the pharmaceutical industry to leap from a large pharmaceutical country to a powerful pharmaceutical country. In this context, from July 31 to August 3, 2021, the 38th annual national pharmaceutical industry information conference was grandly held in Jinan. With the theme of "building a high-energy ecosystem together", the conference linked exogenous forces to jointly promote the improvement of all factor quality and efficiency and kinetic energy conversion of the ecosystem from multiple dimensions such as policy environment, innovation ecology, cross-border integration and capital pattern.

2021 is the first year of the "14th five year plan" and the historical intersection of the "two centenary" goals. It is also a key period for the pharmaceutical industry to leap from a large pharmaceutical country to a powerful pharmaceutical country. In this context, from July 31 to August 3, 2021, the 38th annual national pharmaceutical industry information conference was grandly held in Jinan. With the theme of "building a high-energy ecosystem together", the conference linked exogenous forces to jointly promote the improvement of all factor quality and efficiency and kinetic energy conversion of the ecosystem from multiple dimensions such as policy environment, innovation ecology, cross-border integration and capital pattern.

Company introduction

Founded in 1970 and headquartered in Wenling City, Taizhou, Zhejiang Province, wanbond Pharmaceutical Group is a high-tech enterprise specializing in the R & D, production and sales of modern traditional Chinese medicine, chemical APIs and preparations. It is the core enterprise of the listed company wanbond pharmaceutical Holding Group Co., Ltd. (Stock Code: 002082). In 2020, it was rated as "the most growing enterprise in China's pharmaceutical industry" and "the top 100 brand enterprises of Chinese national medicine in 2019", won the title of "the most influential list in China's pharmaceutical industry in 2019 - the top 50 growing enterprises in China's pharmaceutical industry in 2019", and was selected as "the top 100 Chinese patent medicine enterprises in 2020".
Wanbond Pharmaceutical Group always adheres to the road of industry university research integration, has a mature technology transformation platform, and has "academician expert workstation", "Zhejiang University wanbond Joint Research Center for the modernization of traditional Chinese medicine", "China Pharmaceutical University wanbond drug joint R & D center", "provincial enterprise Research Institute of cardiovascular and cerebrovascular drugs" and "provincial enterprise technology center" "The first collaborative innovation alliance of medical research enterprises of pharmaceutical products in China - ginkgo leaf dropping pill collaborative innovation alliance of medical research enterprises", and participated in the drafting of a number of national pharmacopoeia standards. The registered trademark of the company is recognized as a well-known trademark in China.
At present, wanbond Pharmaceutical Group has formed "taking natural botanical drugs as the characteristics, focusing on drugs for cardio cerebrovascular and nervous system, supplemented by drugs for respiratory system and other fields" The company's products cover many treatment fields such as cardiovascular and cerebrovascular diseases, nervous system diseases, respiratory diseases and digestive system diseases. At present, the company has 192 drug production approval numbers, involving 16 dosage forms. It has two core products with full intellectual property rights: huperzine a raw material and injection, the world's first, and ginkgo leaf dropping pills, the domestic exclusive protected variety of traditional Chinese medicine.